NEW YORK, Sept. 26 - Paradigm Genetics has met a fifth milestone in an agricultural gene-discovery partnership with Monsanto Company, triggering an undisclosed accelerated milestone payment, the functional genomics company said on Wednesday.

Paradigm also announced that Monsanto has amended the partnership by removing its termination option in exchange for broader rights. “This amendment is significant since it commits Monsanto to a total term of at least six years, with options to extend the scope of work in time and volume,” Paradigm said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.